DSCAM and Down syndrome: Recent findings in iPSC-derived cerebral organoids from patients with Down syndrome showed that inhibiting the DSCAM–PAK1 pathway restored impaired neurogenesis, demonstrating that excessive PAK1 signaling can be targeted with drugs in a neurodevelopmental setting [71].